We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

521 hedge funds and large institutions have $31.8B invested in Alexion Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 183 increasing their positions, 209 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 48

6% more capital invested

Capital invested by funds: $30B → $31.8B (+$1.85B)

0% more funds holding

Funds holding: 521 → 521 (0)

12% less repeat investments, than reductions

Existing positions increased: 183 | Existing positions reduced: 209

13% less funds holding in top 10

Funds holding in top 10: 15 → 13 (-2)

22% less call options, than puts

Call options by funds: $126M | Put options by funds: $160M

Holders
521
Holders Change
–
Holders Change %
0%
% of All Funds
15.12%
Holding in Top 10
13
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-13.33%
% of All Funds
0.38%
New
55
Increased
183
Reduced
209
Closed
48
Calls
$126M
Puts
$160M
Net Calls
-$34.5M
Net Calls Change
+$21.5M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$395M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$393M
3
Winslow Capital Management
Winslow Capital Management
Minnesota
+$81.1M
4
American Century Companies
American Century Companies
Missouri
+$80.3M
5
Jennison Associates
Jennison Associates
New York
+$38.6M

Top Sellers

1
Norges Bank
Norges Bank
Norway
-$217M
2
BFA
BlackRock Fund Advisors
California
-$124M
3
Wells Fargo
Wells Fargo
California
-$120M
4
Millennium Management
Millennium Management
New York
-$119M
5
AL
AJO LP
Pennsylvania
-$71.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital Research Global Investors
1
Capital Research Global Investors
California
$4.02B +$1.68M +10,235 +0%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$3.33B +$393M +2,392,465 +14%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$3.27B +$395M +2,405,193 +14%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.7B +$31.5M +191,822 +2%
Jennison Associates
5
Jennison Associates
New York
$1.39B +$38.6M +234,768 +3%
State Street
6
State Street
Massachusetts
$1.35B +$34.6M +210,651 +3%
JP Morgan Chase
7
JP Morgan Chase
New York
$1.12B -$47.5M -289,020 -4%
Sands Capital Management
8
Sands Capital Management
Virginia
$881M +$5.21M +31,706 +0.6%
BIT
9
BlackRock Institutional Trust
California
$841M -$1.9M -11,552 -0.2%
Wells Fargo
10
Wells Fargo
California
$747M -$120M -731,184 -14%
BFA
11
BlackRock Fund Advisors
California
$559M -$124M -756,502 -18%
Winslow Capital Management
12
Winslow Capital Management
Minnesota
$558M +$81.1M +493,654 +17%
Invesco
13
Invesco
Georgia
$555M -$69.3M -421,756 -11%
American Century Companies
14
American Century Companies
Missouri
$540M +$80.3M +489,231 +18%
Ameriprise
15
Ameriprise
Minnesota
$492M +$29.6M +180,277 +6%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$462M -$827K -5,038 -0.2%
Northern Trust
17
Northern Trust
Illinois
$426M +$2.81M +17,081 +0.7%
Viking Global Investors
18
Viking Global Investors
Connecticut
$365M +$31.6M +192,359 +10%
Massachusetts Financial Services
19
Massachusetts Financial Services
Massachusetts
$353M +$2.16M +13,164 +0.6%
TCIM
20
TIAA CREF Investment Management
New York
$338M +$7.81M +47,551 +2%
BG
21
BlackRock Group
United Kingdom
$329M +$3.79M +23,059 +1%
DCP
22
DSM Capital Partners
Florida
$265M +$1.15M +7,007 +0.4%
Artisan Partners
23
Artisan Partners
Wisconsin
$246M -$53.9M -327,910 -18%
Geode Capital Management
24
Geode Capital Management
Massachusetts
$235M -$7.3M -44,478 -3%
BA
25
BlackRock Advisors
Delaware
$225M -$8.12M -49,437 -4%
1
2 3 4 5

ALXN Hedge Fund Activity: Q3 2014 in Review

521 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2014, worth a combined $31.8B — up 6.2% from $30B a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new ALXN positions and 48 closed out — a net gain of 7 holders — while 183 added to existing stakes and 209 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $395M. The largest seller was Norges Bank, cutting an estimated $217M.

  • 521 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2014, unchanged from Q2 2014.
  • Funds reported $31.8B of Alexion Pharmaceuticals stock for Q3 2014, up 6.2% quarter-over-quarter.
  • 55 funds opened new Alexion Pharmaceuticals positions in Q3 2014 and 48 closed out, a net change of +7 holders.
  • The largest Alexion Pharmaceuticals buyer in Q3 2014 was T. Rowe Price Associates, an estimated $395M added.
  • The largest Alexion Pharmaceuticals seller in Q3 2014 was Norges Bank, an estimated $217M sold.

Based on aggregated 13F filings for Q3 2014.